U.S. markets closed
  • S&P Futures

    4,366.00
    +17.75 (+0.41%)
     
  • Dow Futures

    34,027.00
    +188.00 (+0.56%)
     
  • Nasdaq Futures

    15,057.75
    +48.25 (+0.32%)
     
  • Russell 2000 Futures

    2,188.60
    +11.80 (+0.54%)
     
  • Crude Oil

    70.98
    +0.69 (+0.98%)
     
  • Gold

    1,763.60
    -0.20 (-0.01%)
     
  • Silver

    22.26
    +0.06 (+0.27%)
     
  • EUR/USD

    1.1736
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3670
    +0.0011 (+0.08%)
     
  • USD/JPY

    109.6020
    +0.1820 (+0.17%)
     
  • BTC-USD

    42,785.42
    -2,827.63 (-6.20%)
     
  • CMC Crypto 200

    1,069.82
    -64.56 (-5.69%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    29,898.57
    -601.48 (-1.97%)
     

Meridian To Buy Urea Breath Test For H. Pylori From Otsuka America Pharmaceutical For $20M

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Meridian Bioscience Inc (NASDAQ: VIVO) has agreed to acquire the North American BreathTek business from Otsuka America Pharmaceutical Inc for $20 million in cash.

  • The transaction will close in Meridian's fiscal fourth quarter, which ends in September.

  • With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test to detect Helicobacter pylori.

  • Meridian expects the acquisition to add more than $20 million of annual revenue, enhancing its diagnostics segment. The deal will be accretive to earnings and cash immediately.

  • As of 31 March, the company reported cash and cash equivalents were .4 million and $110 million of borrowing capacity under its $160.0 million commercial bank credit facility.

  • Price Action: VIVO shares are up 0.21% at $18.98 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.